1. Chopra HK
2. Sharma Pawan K

9789354653933

10.5005/jp/books/18566_150

1/e

2022

5

1. Moolchand Medcity Hospital, New Delhi, India, Medanta Moolchand Heart Institute, Moolchand Medcity, New Delhi, India, Medanta Moolchand Heart Institute, Moolchand Medcity; World Wellness Foundation, WHA; AHA, Medanta Moolchand Heart Institute; Moolchand Medcity; World Wellness Foundation, WHA; CSI & IAE; IHJ, JIAE, Medanta Moolchand Heart Institute; Moolchand Medcity; World Wellness Foundation, WHA, Medanta Moolchand Heart Institute, New Delhi, India; CME, Moolchand Medcity, World Wellness, Foundation and WHA; AHA; CSI and IAE; IHJ and JIAE, IAE-2017, CSI-2015; World Wellness Foundation, Country Head, American Heart Association; Medanta Moolchand Heart Institute; Health Committee, SCOPE, Tata Sky FAM Health, New Delhi, India, IAE- 2017, CSI -2015; World Wellness Foundation; American Heart Association; Moolchand Medcity; Physician Governing Body, CME, COP Moolchand Medcity, New Delhi, India, IAE- 2017, CSI -2015; World Wellness Foundation; Physician Governing Body, CME, COP Moolchand Medcity, New Delhi, India
2. St Mark’s Hospital, Salt Lake City, Utah, USA, University of Utah School of Medicine, Salt Lake City, Utah, USA, Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA

PCSK9 inhibitor, lipid lowering agent, low-density lipoprotein-cholesterol, high- density lipoprotein cholesterol, C-reactive protein, CRP